Provided by Tiger Fintech (Singapore) Pte. Ltd.

Turnstone Biologics Corp.

0.3330
-0.0034-1.01%
Volume:15.27K
Turnover:5.08K
Market Cap:7.71M
PE:-0.11
High:0.3500
Open:0.3291
Low:0.3291
Close:0.3364
Loading ...

Company Profile

Company Name:
Turnstone Biologics Corp.
Exchange:
NASDAQ
Establishment Date:
2014
Employees:
14
Office Location:
9310 Athena Circle,Suite 300,San Diego,California,United States
Zip Code:
92037
Fax:
- -
Introduction:
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.

Directors

Name
Position
Jerel Davis
Director and Chairman
Sammy Farah
President, Chief Executive Officer and Director
Michael Burgess
Interim Chief Medical Officer and Director
Kanya Rajangam
Director
Patrick Machado
Director
Rishi Gupta
Director
Robert Gould
Director
Santhosh Palani
Director
Stefan Larson
Director

Shareholders

Name
Position
Sammy Farah
President, Chief Executive Officer and Director
Venkat Ramanan
Chief Financial Officer
Michael Burgess
Interim Chief Medical Officer and Director
P. Joseph Campisi
Chief Legal Officer
Saryah Azmat
Chief Business Officer
Stewart Abbot
Chief Scientific Officer
Vijay Chiruvolu
Interim Chief Technology Officer